Dr Byram W. Bridle warns
"We made a big mistake. We didn't know that the spike
protein was a toxin."
Question of long term safety
(Radio Interview based on recent peer reviewed studies)
Dr Byram W. Bridle
Associate Professor | PhD
viral immunologist
Who is he?
##
https://ovc.uoguelph.ca/pathobiology/people/faculty/Byram-W-Bridle
Byram W. Bridle
Associate Professor | PhD
Dr. Bridle is a viral immunologist who is passionate about
improving life through two avenues of research. One arm of
his research program is dedicated to designing and
optimizing novel biotherapies for the treatment of cancers.
The second arm of his research program focuses on studying
host responses to viruses and other inflammatory stimuli.
The Bridle lab is harnessing their expertise in making
potent cancer vaccines and combining this with their
interest in anti-viral immunity to develop vaccines to
protect against infectious diseases such as those caused by
highly pathogenic coronaviruses. Mentoring the next
generation of Canadian scientists
##
In the radio interview he says
Assumption up until now - shoulder muscle.
BUT new cutting edge science
request for information. Biodistribution study - where the
messenger RNA goes???
Spike protein gets into the blood of individuals
accumulates in spleen, liver, bone marrow, ovaries
##
Radio interview available here
https://omny.fm/shows/on-point-with-alex-pierson/new-peer-reviewed-study-on-covid-19-vaccines-sugge
#
LINKS TO HIS "RECENT PEER REVIEWED STUDIES"
########################
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab465/6279075
(Pdf3)
https://www.mdpi.com/2673-527X/1/1/4, ;
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827936/;
(PDF 4a / 4b)
###################
It was assumed that the spike proteins do not end up in
circulation; however, this is being challenged by recent
studies.
Ogata et al., 20213 reported the detection of spike protein
in the plasma of 3 of 13 young healthcare workers following
vaccination with Moderna’s mRNA-1273 vaccine. In one of the
workers, the spike protein circulated for 29 days. The data
are limited and warrant further investigation for both the
Moderna and Pfizer BioNTech COVID-19 vaccines.
refers to THIS LINK
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab465/6279075
Recent studies indicate the spike protein, itself, may
potentially be harmful.
https://www.mdpi.com/2673-527X/1/1/4, ;
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827936/;
################
LINKS and some notes
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab465/6279075
critical data demonstrating the direct production of spike
protein via translation from the mRNA-1273 vaccine in these
studies are missing, precluding a full understanding of the
vaccine mechanism.
Here, we provide evidence that circulating SARS-CoV-2
proteins are present in the plasma of participants
vaccinated with the mRNA-1273 vaccine. We report antigen and
serological data of the mRNA-1273 vaccine in 13 healthcare
workers at the Brigham and Women’s Hospital
detection of SARS-CoV-2 antigens spike (S1-S2 unit),
A prospective pilot study of 13 healthcare workers, 18 years
and older, with no known history of SARS-CoV-2 infection was
conducted at the Brigham and Women’s Hospital from December
2020 to March 2021.
Authors detected S1 and N in 64% of COVID-19 positive
patients and S1 levels were significantly associated with
disease severity. Here, antigens S1 and spike were measured
to probe mRNA translation, while nucleocapsid antigen served
as a negative control
Spike protein was detectable in three of 13 participants an
average of 15 days after the first injection.
We hypothesize that the cellular immune responses triggered
by T-cell activation, which would occur days after the
vaccination, lead to direct killing of cells presenting
spike protein and an additional release of spike into the
blood stream9
Nonetheless, evidence of systemic detection of spike and S1
protein production from the mRNA-1273 vaccine is significant
and has not yet been described in any
These data show that S1 antigen production after the initial
vaccination can be detected by day one and is present beyond
the site of injection and the associated regional lymph
nodes
###############
###############
###############
##############
Recent studies indicate the spike protein, itself, may
potentially be harmful.
https://www.mdpi.com/2673-527X/1/1/4, ;
SARS-CoV-2 Spike Protein and Lung Vascular Cells
patients who have died
of COVID-19 have thickened pulmonary vascular walls, linking
the spike protein to a fatal disease
SARS-CoV-2 spike protein a ecting lung vascular cells
Since the SARS-CoV-2 spike
protein will be administered to millions of people as
COVID-19 vaccines, it is critical to understand
the biological e ects of this protein on human cells to
ensure that it does not promote long-term
adverse health consequences.
The SARS-CoV-2 spike protein consists of two subunits:
Subunit 1 (S1) that contains the ACE2
receptor-binding domain (RBD) and Subunit 2 (S2) that
participates in viral cell membrane fusion [3,6].
Since it is a well-conserved and exposed region of the
virus, the spike protein has been used as the
molecule to acquire immunity in the COVID-19 vaccines.
the SARS-CoV-2
spike protein elicits cell signaling in human host cells
without the rest of the virus
This review article describes the finding of the SARS-CoV-2
spike protein a ecting lung vascular
cells and explains how the spike protein (as a component of
SARS-CoV-2, as well as the molecule
used in COVID-19 vaccines) possibly increases the incidence
of a fatal disease, pulmonary arterial
hypertension (PAH).
We conclude that it is critical to
understand the biological actions of the SARS-CoV-2 spike
protein in a ecting human cells and possibly
promoting long-term adverse health consequences, given that
this protein will be administered to
millions and possibly billions of people as vaccines.
Given that this protein will
be administered as vaccines to millions and possibly
billions of people, it is critical to understand
the extracellular and intracellular e ects of the SARS-CoV-2
spike protein on human cells that may
promote long-term adverse health consequences.
######################
#######################
Recent studies indicate the spike protein, itself, may
potentially be harmful.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827936/;
SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human
HostCells: Implications for Possible Consequences of
COVID-19Vaccines
Thus, it is important to be aware that the spikeprotein
produced by the new COVID-19 vaccines may also affect the
host cells
Further investigations on the effects of the SARS-CoV-2
spike protein on humancells and appropriate experimental
animal models are warranted
Pfizer andBioNTech announced that their mRNA-based vaccine
candidate, BNT162b2,
BNT162b2 encodes the SARS-CoV-2 spike protein to elicit
virus-neutralizingantibodies
More specifically, it encodes the full-length spike protein
of SARS-CoV-2 with twoamino acids mutated to proline in the
S2 subunit to maintain the prefusion conformation, while
itssister vaccine BNT162b1 (also from Pfizer/BioNTech)
encodes only the RBD of the SARS-CoV-2spike protein,
trimerized by
Long-termconsequences of these vaccines are, however,
unknown.
Another promising vaccine, mRNA-1273 by Moderna, is also an
RNA vaccine that encodes the full-length SARS-CoV-2 spike
protein
Viral vector-based vaccines such as AZD1222 by AstraZeneca,
all express the SARS-CoV-2spike protein.
These vaccines as well as many others under development
] introduce the SARS-CoV-2 spike protein into our body, so
that the production of antibodiesand immunity against
SARS-CoV-2 are stimulated.
The different effects of the full-length S1 and RBD
only-containing proteins may be importantconsidering that
BNT162b2 and many other COVID-19 vaccines express the
full-length spike protein,while the BNT162b1 vaccine encodes
only the RBD region
Our laboratory only tested the effects of the SARS-CoV-2
spike protein in lung vascular cells and thoseimplicated in
the development of PAH. However, this protein may also
affect the cells of systemic andcoronary vasculatures,
eliciting other cardiovascular diseases such as coronary
artery disease, systemichypertension, and stroke. In
addition to cardiovascular cells, other cells that express
ACE2 have thepotential to be affected by the SARS-CoV-2
spike protein, which may cause adverse pathologicalevents.
Thus, it is important to consider the possibility that the
SARS-CoV-2 spike protein produced bythe new COVID-19
vaccines triggers cell signaling events that promote PAH,
other cardiovascularcomplications, and/or complications in
other tissues/organs in certain individuals
######
(checking - Pfizer /Comirnaty / BNT162b2 is the full
spike protein)
https://clinicaltrials.gov/ct2/show/NCT04862806
Safety, Efficacy of BNT162b2 mRNA Vaccine in CLL
########
#####################
(((2 months before, this same doctor did not think there was
anything wrong with the vaccines, but has recently changed -
as per below article
https://www.wellingtonadvertiser.com/u-of-g-scientists-concerned-about-extended-interval-between-covid-19-vaccine-doses/
U of G scientists concerned about extended interval between
COVID-19 vaccine doses
Bridle: 'Science relies on empirical data and there is no
data to prove the four-month interval will work'
Joanne ShuttleworthMarch 24, 2021 @ 4:01 pmCOVID-19, New
GUELPH – A group of virologists and immunologists at the
University of Guelph wants the provincial government to put
the brakes on its directive to extend the period between
doses of the Pfizer and Moderna COVID-19 vaccines to four
months.
It’s not that there’s anything wrong with the vaccines, said
Dr. Byram Bridle, a viral immunologist in the department of
pathology.
“We very much promote vaccination,” he said in an interview
on March 18.
“As scientists, we are simply trying to say, follow proper
scientific protocols. Science relies on empirical data and
there is no data to prove the four-month interval will
work.”
######
((Another recent study on the damage from the Spike protein.
https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.121.318902
SARS-CoV-2 Spike Protein Impairs Endothelial Function via
Downregulation of ACE 2
Originally published 31 Mar 2021
SARS-CoV-1 S protein promotes lung injury by decreasing the
level of ACE2 in the infected lungs.3 In the current study,
we show that S protein alone can damage vascular endothelial
cells (ECs) by downregulating ACE2 and consequently
inhibiting mitochondrial function.
#####
Dr Byram W. Bridle
Recently got the Japanese data from the Pfizer study about
where the vaccine spreads in the body
https://www.pmda.go.jp/drugs/2021/P20210212001/672212000_30300AMX00231_I100_1.pdf#page=16
Note that this matches the Europe data from Pfizer
https://www.ema.europa.eu/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf
Pfizer/Comirnaty
studied in rats
((Page 47))
Over 48 hours, distribution was mainly observed to liver,
adrenal glands, spleen and ovaries, with maximum
concentrations observed at 8-48 hours post-dose.